TransCode Therapeutics Statistics
Total Valuation
RNAZ has a market cap or net worth of $5.86 million. The enterprise value is -$6.97 million.
Important Dates
The last earnings date was Friday, May 15, 2026, after market close.
| Earnings Date | May 15, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RNAZ has 950,302 shares outstanding. The number of shares has increased by 1,515.08% in one year.
| Current Share Class | 950,302 |
| Shares Outstanding | 950,302 |
| Shares Change (YoY) | +1,515.08% |
| Shares Change (QoQ) | +0.43% |
| Owned by Insiders (%) | 0.13% |
| Owned by Institutions (%) | 6.63% |
| Float | 865,764 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 4.52 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.11
| Current Ratio | 3.11 |
| Quick Ratio | 2.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,591.28 |
Financial Efficiency
Return on equity (ROE) is -52.14% and return on invested capital (ROIC) is -18.85%.
| Return on Equity (ROE) | -52.14% |
| Return on Assets (ROA) | -17.13% |
| Return on Invested Capital (ROIC) | -18.85% |
| Return on Capital Employed (ROCE) | -15.38% |
| Weighted Average Cost of Capital (WACC) | 11.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.64M |
| Employee Count | 12 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, RNAZ has paid $457,377 in taxes.
| Income Tax | 457,377 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.39% in the last 52 weeks. The beta is 1.40, so RNAZ's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -24.39% |
| 50-Day Moving Average | 8.48 |
| 200-Day Moving Average | 9.73 |
| Relative Strength Index (RSI) | 23.07 |
| Average Volume (20 Days) | 7,324 |
Short Selling Information
The latest short interest is 35,757, so 3.76% of the outstanding shares have been sold short.
| Short Interest | 35,757 |
| Short Previous Month | 41,071 |
| Short % of Shares Out | 3.76% |
| Short % of Float | 4.13% |
| Short Ratio (days to cover) | 6.27 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -23.35M |
| Pretax Income | -39.90M |
| Net Income | -43.70M |
| EBITDA | -23.26M |
| EBIT | -23.35M |
| Earnings Per Share (EPS) | -$49.89 |
Full Income StatementBalance Sheet
The company has $12.84 million in cash and n/a in debt, with a net cash position of $12.84 million or $13.51 per share.
| Cash & Cash Equivalents | 12.84M |
| Total Debt | n/a |
| Net Cash | 12.84M |
| Net Cash Per Share | $13.51 |
| Equity (Book Value) | 144.52M |
| Book Value Per Share | 1.36 |
| Working Capital | 11.37M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$21.40 million and capital expenditures -$6,660, giving a free cash flow of -$21.40 million.
| Operating Cash Flow | -21.40M |
| Capital Expenditures | -6,660 |
| Depreciation & Amortization | 86,939 |
| Net Borrowing | n/a |
| Free Cash Flow | -21.40M |
| FCF Per Share | -$22.52 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RNAZ does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,515.08% |
| Shareholder Yield | -1,515.08% |
| Earnings Yield | -745.23% |
| FCF Yield | -365.04% |
Analyst Forecast
The average price target for RNAZ is $280.00, which is 4,438.01% higher than the current price. The consensus rating is "Buy".
| Price Target | $280.00 |
| Price Target Difference | 4,438.01% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 15, 2025. It was a reverse split with a ratio of 1:28.
| Last Split Date | May 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:28 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
